// App-Quantinova.ai

EP988 : POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE AFTER 1 PRIOR LINE OF THERAPY IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: A SAFETY SUBANALYSIS OF THE PHASE 3 OPTIMISMM TRIAL

Researchers

Presenter

  • Katja Weisel

Principal Investigators

  • Meletios Dimopoulos

  • Albert Oriol

  • Meral Beksac

  • Fredrick Schjesvold

  • Anna Marina Liberati

  • Jindriska Lindsay

  • Darrell White

  • Jesus San Miguel

  • Philippe Moreau

  • Larry D. Anderson Jr

  • Alessandra Lorocca

  • Pawel Robak

  • Prisca Vogel

  • Ruiyun Jiang

  • Lara Grote

  • Teresa Peluso

  • Paul Richardson

Medical Centers

  • UT Southwestern Medical Center, Dallas, Texas, United States

  • A.O.U. Citta della Salute e della Scienza di Torino, Torino, Italy

  • University Hospital Hotel-Dieu, Nantes, France

  • Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland

  • Oslo Myeloma Center, Oslo University Hospital, Oslo, Norway and K.G. Jebsen Centre for B cell malignancies, University of Oslo, Oslo, Norway

  • University of Perugia, Terni, Perugia, Italy

  • Division of Hematologic Malignancy, Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA,

  • Clinica Universidad de Navarra-CIMA, IDISNA, CIBERONC, Pamplona, Spain

  • Bristol Meyers Squibb,Princeton,United States

  • Celgene International Sàrl, a Bristol Myers Squibb Company, Boudry, Switzerland

  • Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Josep Carreras Research Institute,Badalona,Spain

  • National and Kapodistrian University of Athens, Athens, Greece

  • Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada

  • Ankara University, Ankara, Turkey

  • Department of Oncology, Haematology and Bone Marrow Transplantation with section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

  • East Kent Hospitals University NHS Foundation Trust, Kent & Canterbury Hospital, Canterbury, United Kingdom

Locations

  • United States

  • Italy

  • France

  • Poland

  • Norway

  • Spain

  • Switzerland

  • Greece

  • Canada

  • Turkey

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pomalidomide

  • CC-4047

  • Bortezomib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved